Cargando…
Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review)
Bile acids (BAs) are the major components of bile and products of cholesterol metabolism. Cholesterol is catalyzed by a variety of enzymes in the liver to form primary BAs, which are excreted into the intestine with bile, and secondary BAs are formed under the modification of the gut microbiota. Mos...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450808/ https://www.ncbi.nlm.nih.gov/pubmed/35929515 http://dx.doi.org/10.3892/ijo.2022.5407 |
_version_ | 1784784607896403968 |
---|---|
author | Luo, Wenyu Guo, Shiqi Zhou, Yang Zhu, Junfeng Zhao, Jingwen Wang, Mengyao Sang, Lixuan Wang, Bingyuan Chang, Bing |
author_facet | Luo, Wenyu Guo, Shiqi Zhou, Yang Zhu, Junfeng Zhao, Jingwen Wang, Mengyao Sang, Lixuan Wang, Bingyuan Chang, Bing |
author_sort | Luo, Wenyu |
collection | PubMed |
description | Bile acids (BAs) are the major components of bile and products of cholesterol metabolism. Cholesterol is catalyzed by a variety of enzymes in the liver to form primary BAs, which are excreted into the intestine with bile, and secondary BAs are formed under the modification of the gut microbiota. Most of the BAs return to the liver via the portal vein, completing the process of enterohepatic circulation. BAs have an important role in the development of hepatocellular carcinoma (HCC), which may participate in the progression of HCC by recognizing receptors such as farnesoid X receptor (FXR) and mediating multiple downstream pathways. Certain BAs, such as ursodeoxycholic acid and obeticholic acid, were indicated to be able to delay liver injury and HCC progression. In the present review, the structure and function of BAs were introduced and the metabolism of BAs and the process of enterohepatic circulation were outlined. Furthermore, the mechanisms by which BAs participate in the development of HCC were summarized and possible strategies for targeting BAs and key sites of their metabolic processes to treat HCC were suggested. |
format | Online Article Text |
id | pubmed-9450808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-94508082022-09-19 Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review) Luo, Wenyu Guo, Shiqi Zhou, Yang Zhu, Junfeng Zhao, Jingwen Wang, Mengyao Sang, Lixuan Wang, Bingyuan Chang, Bing Int J Oncol Articles Bile acids (BAs) are the major components of bile and products of cholesterol metabolism. Cholesterol is catalyzed by a variety of enzymes in the liver to form primary BAs, which are excreted into the intestine with bile, and secondary BAs are formed under the modification of the gut microbiota. Most of the BAs return to the liver via the portal vein, completing the process of enterohepatic circulation. BAs have an important role in the development of hepatocellular carcinoma (HCC), which may participate in the progression of HCC by recognizing receptors such as farnesoid X receptor (FXR) and mediating multiple downstream pathways. Certain BAs, such as ursodeoxycholic acid and obeticholic acid, were indicated to be able to delay liver injury and HCC progression. In the present review, the structure and function of BAs were introduced and the metabolism of BAs and the process of enterohepatic circulation were outlined. Furthermore, the mechanisms by which BAs participate in the development of HCC were summarized and possible strategies for targeting BAs and key sites of their metabolic processes to treat HCC were suggested. D.A. Spandidos 2022-08-05 /pmc/articles/PMC9450808/ /pubmed/35929515 http://dx.doi.org/10.3892/ijo.2022.5407 Text en Copyright: © Luo et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Luo, Wenyu Guo, Shiqi Zhou, Yang Zhu, Junfeng Zhao, Jingwen Wang, Mengyao Sang, Lixuan Wang, Bingyuan Chang, Bing Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review) |
title | Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review) |
title_full | Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review) |
title_fullStr | Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review) |
title_full_unstemmed | Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review) |
title_short | Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review) |
title_sort | hepatocellular carcinoma: novel understandings and therapeutic strategies based on bile acids (review) |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450808/ https://www.ncbi.nlm.nih.gov/pubmed/35929515 http://dx.doi.org/10.3892/ijo.2022.5407 |
work_keys_str_mv | AT luowenyu hepatocellularcarcinomanovelunderstandingsandtherapeuticstrategiesbasedonbileacidsreview AT guoshiqi hepatocellularcarcinomanovelunderstandingsandtherapeuticstrategiesbasedonbileacidsreview AT zhouyang hepatocellularcarcinomanovelunderstandingsandtherapeuticstrategiesbasedonbileacidsreview AT zhujunfeng hepatocellularcarcinomanovelunderstandingsandtherapeuticstrategiesbasedonbileacidsreview AT zhaojingwen hepatocellularcarcinomanovelunderstandingsandtherapeuticstrategiesbasedonbileacidsreview AT wangmengyao hepatocellularcarcinomanovelunderstandingsandtherapeuticstrategiesbasedonbileacidsreview AT sanglixuan hepatocellularcarcinomanovelunderstandingsandtherapeuticstrategiesbasedonbileacidsreview AT wangbingyuan hepatocellularcarcinomanovelunderstandingsandtherapeuticstrategiesbasedonbileacidsreview AT changbing hepatocellularcarcinomanovelunderstandingsandtherapeuticstrategiesbasedonbileacidsreview |